Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have received an average rating of “Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $43.75.
Several research firms have issued reports on DCPH. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a report on Tuesday, November 13th. BidaskClub upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price objective on shares of Deciphera Pharmaceuticals in a report on Thursday, December 20th. B. Riley downgraded Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, January 1st. Finally, Leerink Swann cut their price objective on Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating on the stock in a report on Friday, November 16th.
NASDAQ DCPH traded down $0.97 on Friday, hitting $24.44. 330 shares of the company were exchanged, compared to its average volume of 430,833. The company has a current ratio of 18.46, a quick ratio of 18.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $808.59 million, a PE ratio of -8.28 and a beta of 3.38. Deciphera Pharmaceuticals has a twelve month low of $18.55 and a twelve month high of $45.61.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.65). Research analysts forecast that Deciphera Pharmaceuticals will post -2.62 EPS for the current fiscal year.
In other Deciphera Pharmaceuticals news, CFO Thomas Patrick Kelly sold 5,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $25.18, for a total transaction of $125,900.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 20.61% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc grew its stake in Deciphera Pharmaceuticals by 55.4% during the 3rd quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock valued at $64,000 after acquiring an additional 587 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock valued at $103,000 after buying an additional 1,982 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $235,000. Rhumbline Advisers bought a new stake in shares of Deciphera Pharmaceuticals in the 2nd quarter valued at approximately $301,000. Finally, Highland Capital Management LP bought a new stake in shares of Deciphera Pharmaceuticals in the 2nd quarter valued at approximately $394,000. 55.04% of the stock is currently owned by institutional investors.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.